Anomalous Tumour Marker Concentrations in Renal Transplant Patients by Wood, W. G. et al.
Wood et al.: Tumour markers in renal transplant patients 75
Eur. J. Glin. Chem. Clin. Biochem.
Vol.31, 1993, pp. 75-82
© 1993 Walter de Gruyter & Co.
Berlin · New York
Anomalous Tumour Marker Concentrations in Renal Transplant Patients
By W. G. Wood\ J. Sieinhoff2 and Anne-Christine Kessler3
1 Institut fiir Laboratoriumsdiagnostik, Klinikum der Hansestadt Stralsund, Stralsund
2 Klinik für Innere Medizin, Medizinische Universität zu Lübeck, Lübeck
3 Evaluation Department for Immunology Systems, Boehringer-Mannheim, Tutzing
(Received July 15/October 26, 1992)
Summary: Serial serum determinations of the tumour associated antigens carcinoembryonic antigen, tissue
polypeptide antigen, CA 19-9, CA 15-3 and CA 125 were performed on 70 patients who were undergoing, or
had undergone renal transplantation.
The period of observation ranged from 4 days pre-operative to 708 days post-operative, although daily
monitoring was usually carried out during the first 14—35 days post-operatively.
With the exception of tissue polypeptide antigen, which was analysed with an immunoluminometric assay, all
analytes were measured with the Enzymun-Test® System ES-300 using immunoenzymometric assays with
colorimetric determination. The interassay coefficients of variation were less than 5% for the immunoenzy-
mometric assays and 8.7% for tissue polypeptide antigen, all values being derived from 20 consecutive assays.
Only 8/70 patients with no complications showed normal concentrations for all five analytes. 6/79 patients
showed parallel changes of at least three markers. 7/70 patients had transient elevations of at least one marker,
whereas 25/70 patients had a continual elevation of CA 125, 9/70 CA 19-9 and 1/70 CA 15-3, although no
patient showed evidence of disease. Two patients, each with 2 rejection episodes, showed daily fluctuations
up to 100% for all markers, with the exception of carcinoembryonic antigen. There was no correlation
between elevated tumour markers and cytomegalovirus infection.
° uc on leased into the circulation, thus allowing an early and
Despite the vast amount of research on developing specific detection of malignancies. It was seen how-
in-vitro tests suitable for the early detection of cancer, ever, that the same tumour associated antigens were
the lack of diagnostic sensitivity and specificity has expressed and released in non-malignant states, thus*
prevented such methods being used for screening pur- preventing their use for screening purposes (3).
poses.
_ . ~ „ ,. ,. , . It had been noticed that elevated levels of tumourThis paper follows up earlier reports on dialysis pa- . - . _ A , ._ , _ , _ .._ ,. X*1F , . . - V f* -»\ n r Ji associated antigen CA 125 (CA 125) occurred nottients from this laboratory (1,2), as well as from other , . ° . ; / .
<. /-r/· C· -u * * only in renal haemodialysis (2), but also in advancedmore recent reports (3) m which elevated tumour , - · * · . , , , , / ,4. , ,. * . r « .. ., r liver cirrhosis due to alcohol abuse (1), and the ques-marker concentrations were found in the serum of , , . \ , , ,... , . ^ * -*u * r tlon arose as to whether uraemia and alcoholism maymany dialysis patients, without any evidence of ma- .... Jlead to solubilisation of the membrane-bound tumour
ignancy. associated antigens. This could explain the high CA
As many so-called tumour markers are expressed on 125 concentrations sometimes found in these patients,
the surface of malignant cells (4—6), it was hoped If this were the case, then elevated concentrations
that these tumour associated antigens would be re- should return to normal, at least in the dialysis pa-
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tients, after successful renal transplantation and onset
of diuresis. This hypothesis formed the basis for this
study.
The tumour markers studied were: tissue polypeptide
antigen, as this is known to be eliminated renally (1,
2), carcinoembryonic antigen and the tumour asso-
ciated antigens CA 19-9, CA 15-3 and CA 125.
Similar studies, but using single samples from patients
with chronic renal failure and under renal haemodi-
alysis, have already been published (7-9), although
the results are often different from those found in the
present study.
The observation period covered in this study ranged




Immunoassay kits were purchased from Byk-Sangtec (Dietzen-
bach, D.) for tissue polypeptide antigen (TPA LIA-mat, im-
munoluminometric assay) and from Boehringer-Mannheim
(Mannheim, Germany) for carcinoembryonic antigen and the
tumour associated antigens CA 19-9, CA 15-3 and CA 125
(Enzymun-Test® CEA, CA 19-9, CA 15-3 and CA 125, immu-
noenzymometric assays).
Methods
All analytes were measured according to the manufacturers'
instructions. The tissue polypeptide antigen assay was measured
with a 250 sample semi-automated luminometer (E.G. &
G. Berthold, Wildbad, Germany). The remaining analytes were
measured on the Enzymun-Test® System ES-300 (Boehringer,
Mannheim).
Table 1 shows the reference ranges for these analytes as estab-
lished in the routine laboratory of the author (W. G. W.).
Patients
Seventy patients were studied prospectively over a two year
period. All patients who were admitted to the renal transplant
unit were taken into the study. The study was carried out
between 1989 and 1991 as part of an ongoing study mainly
concerned with the evaluation of urinary proteins in such pa-
tients, the results of which have already been published in part
(10-12).
The five tumour markers were measured daily so long as the
patient was in hospital. This covered the peri- and post-trans-
plant periods, as well as periods where complications occurred,
usually in the form of rejection episodes, but also in cases of
cytomegalovirus infection.
The observation period was from directly before transplanta-
tion up to 708 days post-operatively, although the daily mon-
itoring usually covered a period between 14 and 35 days.
Statistics
Statistics were kept to a minimum, the 2- and 4-field chi-square
test being used when required.
Tab. 1. Reference ranges for the tumour markers used in this
study.
The values are given for the 95th percentile of 102
clinically healthy volunteers aged between 18 and 72
years of age who were non-smokers and who consumed
less than 60 g alcohol per day. No distinction was made
between the sexes. Females on oral contraceptives were







CA 19-9 (CA 19-9)
Tumour Associated Antigen
CA 15-3 (CA 15-3)
Tumour Associated Antigen
CA 125 (CA 125)
<70U/1





* Values above 5 g/l were taken to be elevated.
+ Values were rounded off for routine purposes.
The reference ranges are only Valid for the methods used in
this study and have not been related to "cut-off values with
defined diagnostic sensitivity and specificity.
The 95th percentile was taken as the upper limit as many of
the subjects had tumour marker concentrations below the lower
detection limit of the assays.
Notes upon the analytes measured
Tissue polypeptide antigen — TPA
This marker is known to be eliminated renally, elevated con-
centrations being encountered in oliguric and anuric patients
(1, 2). After onset of diuresis, tissue polypeptide antigen cori^
centrations returned to normal or near normal. Impairment of
renal function, for example as in a rejection episode, inevitably
led to increased tissue polypeptide antigen concentrations,
which correlated with the degree and duration of the episode.
Carcinoembryonic antigen — CEA
This "classical" tumour marker is often seen to be slightly
elevated in patients on chronic haemodialysis (3), and was
studied here for this reason.
Tumour associated antigens — CA 19-9, CA 15-3, CA 125
These markers are known to be elevated in certain patients
with impaired renal function (1 — 3, 7, 9), although the reports
from the literature differ, even for the same marker. All 3
markers are present in epithelial cells.
Assay reproducibility
The median inter-assay coefficients of variation for the assays
carried out on the Enzymun-Test® System ES-300 were less
than 5% over the whole measuring range (derived from 5
control sera covering the whole standard curve for each assay,
measured in at least 20 assays) so that sequential analysis of
the samples (inclusion in routine assays) was carried out. No
difference was seen when all samples from a single patient
analysed in one assay were compared with the results obtained
as above.
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As this was not the case for tissue polypeptide antigen, the
batch analysis of all samples from a single patient was per-
formed as far as was possible. The median inter-assay coefficient
of variation for tissue polypeptide antigen was 8.7% (derived
from 20 assays using the same batch of control sera at three




Patients with no clinical complications post-opera-
tively did not necessarily have normal tumour marker
concentrations in serum.
Only one patient presented with a clinically/histolog-
ically confirmed tumour post-operatively, namely a
non-secreting B-cell lymphoma, which was success-
fully treated.
No apparent correlation was found between the actual
clinical condition and the appearance of elevated tum-
our markers, with the exception of tissue polypeptide
antigen and carcinoembryonic antigen. Correlations
considered were: transplant rejection episodes, viral/
bacterial infections, medication regimes and cyclo-
sporin toxicity.
Specific cases
Parallel changes in at least 3 of the four markers
(excluding tissue polypeptide antigen)
Six of 70 patients showed parallel changes in at least
three of the markers. 4/6 of these patients had at least
one elevated tumour marker. Figures la and Ib are
given as examples of this group.
All tumour concentrations normal in patients with a
clinically uneventful post-transplant period
Eight of 70 patients had normal concentrations of all
5 analytes after an uneventful renal transplant oper-
ation (figs. 2a and 2b).
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Fig. 1. Parallel course of four tumour markers (patients TP-42
(a) and TP40 (b)).
These two examples show the parallel course of all
tumour markers, with the exception of tissue polypep-
tide antigen. In figure la the left ordinate is logarithmic
to accentuate this trend. This type of course was seen
in six of the patients studied. As in the subsequent
figures, the abscissa shows the days after onset of diu-
resis, negative values showing observations prior to this
period. Unless stated otherwise, all observations are in
the post-operative period.
Key to symbols:
π - CA 125,
+ - CA 15-3,
* - CA 19-9,
α — carcinoembryonic antigen,
χ — tissue polypeptide antigen.
Transient elevation of tumour markers in patients with
no complications post-operatively
Seven of 70 patients had transient elevations of at
least one tumour marker post-operatively. Concentra-
tions returned to the reference range for healthy sub-
jects during the first observation period (14 — 35 days).
The elevated markers were: CA 125 (4/7), CA 15-3
(2/7) and CA 19-9 (1/7). Figure 3 typifies this group.
Consistent elevation of single tumour markers without
evidence of malignant disease
Twenty-five of 70 patients showed elevated CA 125
concentrations, 9/70 patients elevated CA 19-9 and
1/70 patients elevated CA 15-3 concentrations. Fig-
ures 4a—4c show an example for each of these three
markers.
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Days after onset of diuresis
Fig. 2. Normal tumour markers, clincally uneventful (patients
TP-08 (a) and TP-28 (b)).
These two pictures show a normal course of events in
patients with no elevated tumour marker concentra-
tions. Figure 2a shows a wash-out effect for all analytes.
Day 0 is one day prior to operation. Figure 2b shows
a similar state of affairs, but where the wash-out phe-
nomenon for carcinoembryonic antigen and tissue poly-
peptide antigen is much clearer. This picture was ob-
served in eight patients.
Key to symbols:
α - CA 125,
+ -CA 15-3,
* - CA 19-9,
— carcinoembryonic antigen,
x - tissue polypeptide antigen.
A case of known malignancy — a non-secreting B-cell
lymphoma (fig. 5)
One patient developed a non-secreting B-cell lym-
phoma, which was clinically confirmed 30 days after
transplantation. The interesting points to note in fig-
ure 5 are: a tissue polypeptide antigen trigger, with
concentrations rising from 155 to 1030 U/l within 4
days, despite unchanged diuresis (2250-2420 ml/
24 h) [days 15-18]; an increase in the CA 19-9 con-
centrations from day 16 (58 kU/1) to day 31 (222
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Fig. 3. Transient elevation of tumour markers (patient TP-27).
This figure shows transient elevations of carcinoem-
bryonic antigen, CA 19-9 and CA 125 which were
slightly elevated in the peri- and early post-operative
phase, but which fell to within the reference range for
healthy subjects within three weeks after transplanta-
tion. Seven patients presented with a similar picture.
Key to symbols:
π - CA 125,
+ - CA 15-3,
* -CA19-9,
D — carcinoembryonic antigen,
x — tissue polypeptide antigen.
during this time. It is intersting to note that although
the lymphoma was cured (normal blood smear), the
CA 19-9 and tissue polypeptide antigen concentra-
tions remained elevated. The serum values on day 708
post op. were: tissue polypeptide antigen 178 U/l, CA
19-9 113 kU/l, CA 15-3 30 kU/1, CA 125 < 6 kU/1,
carcinoembryonic antigen 3.6 μg/l. The concentra-
tions of CA 15-3 were more or less constant and were
borderline (20-32 kU/1). CA 125, although border-
line during the first observation period (18 — 34 kU/1),
was below the detection limit of the assay almost two
years later. Tissue polypeptide antigen remained ele ·̂
vated, despite a normal diuresis. The patient had no
signs of malignant disease on day 708, her transplant
functioned normally and there were no clinical com-
plications.
Two cases of transplant rejection (figs. 6a and 6b)
Case 1.
After intermittent onset of diuresis'(days 2-10) the
course was uneventful until day 24 when the first
signs of rejection were seen (glomerular proteinuria).
After successful treatment with methyl prednisolone,
the patient was discharged οη* day 43. A second re-
jection episode was confirmed on day 69, which was
successfully treated, the patient being discharged on
day 106. During the second rejection episode, CA 19-9
Eu*. J. Clhi. Chem. Clin. Biochem. / Vol. 31,1993 / No. 2
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Days after onset of diuresis
Fig. 4. Persistently elevated single tumour marker concentra-
tions without clinical complications (patients TP-35 (a),
TP-12 (b) and TP-01 (c)).
This was the most common picture, 25 of the 70 patients
showing such a constellation. Figure 4a shows the re-
sults for CA 125 (25 cases), figure 4b for CA 19-9 (9
cases) and figure 4c for CA 15-3 (one case). The con-
centrations of CA 125 were on average much higher
than for the other two CA-markers. In figure 4c day
— 5 is 1 day prior to operation.
Key to symbols:
Β — CA 125, D — carcinoembryonic antigen,
4- — CA 15-3, χ — tissue polypeptide antigen.
* -CA19-9,
8 12 16 20 24










Fig. 5. The isolated case of a malignant process following renal
transplantation, the occurence of a non-secreting B-cell
lymphoma (patient TP-03).
This shows the course of events of the patient described
in the text. Such elevations of tissue polypeptide antigen
and CA 19-9 were not seen in any other of the patients
observed. It may be that the rapid progression of values
is more important than a single observed value. It is
most probable that the immunosuppressive treatment
after transplantation led to the rapid development of
the lymphoma. The serum tumour marker values 708
days after transplantation are listed in the text.
Key to symbols:
α -CA125,
+ - CA 15-3,
* -CA19-9,
ο — carcinoembryonic antigen,
x — tissue polypeptide antigen.
and tissue polypeptide antigen concentrations showed
daily variations not seen in uncomplicated cases. Con-
centrations of CA 15-3 were much less affected and
CA 125 concentrations first became detectable during
the second rejection episode. Carcinoembryonic an-
tigen concentrations fluctuated, although these re-
mained within the healthy reference range. CA 19-9
concentrations were elevated during and after the first
rejection episode. Tissue polypeptide antigen concen-
trations remained within the reference range during
both rejection episodes.
Case 2.
This patient showed no complications until day 55
when transplant rejection signs were seen. After suc-
cessful treatment (methyl prednisolone), the patient
was dicharged (day 70), only to be readmitted on day
96 with similar symptoms. Drugs used for treatment
of the second rejection episode included methyl pred-
nisolone and anti-lymphocyte globulins.
The interesting point to note is again the large day to
day variation in all tumour markers, with the excep-
tion of carcinoembryonic antigen, which remained
below 2 μg/l throughout the study period. In contrast
Eur. J. Clin. Chera. din. Biochem./ Vol. 31,1993/No. 2
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Fig. 6. Rejection episodes after renal transplantation (patients
TP-22(a)andTP-16(b)).
In the 70 patients observed, 29 rejection episodes were
monitored, four of which are exemplified in the two
patients presented in these figures. The periods con-
necting the episodes, and lying outside the periods of
interest have been included to show any trends in values
between the observation periods. The problem periods
and rejection episodes in patient TP-22 (fig. 6a) were of
longer duration than those in patient TP-16 (fig. 6b),
although the amplitude of the variations in the latter
patient were greater. Please note the logarithmic left
ordinate in figure 6b, again used for clarity. In figure
6b day -4 is 1 day prior to transplantation.
Key to symbols:
n - CA 125,
+ - CA 15-3,
* - CA 19-9,
D — carcinoembryonic antigen,
χ - tissue polypeptide antigen.
to case 1, the tissue polypeptide antigen concentra-
tions oscillated between the upper limit of the refer-
ence range and values twice as high. During episodes,
variations of up to 60 U/l occurred from day to day.
Correlation between elevated tumour markers and cy-
tomegalovirus infection
There was no correlation between the incidence of an
elevated tumour marker and a cytomegalovirus infec-
tion or cytomegalovirus-positive donor organ. This is
in contrast to the isolated 2-microglobulinuria seen
in cytomegalovirus infections (10 p 12).
From the 37 patients, which were positive for cyto-
megalovirus (either as an infection (17/37) or in the
constellation donor cytomegalovirus positive 36/37),
21 had at least one elevated tumour marker (excluding
tissue polypeptide antigen). From the remaining 33
patients, who had no cytomegalovirus infection and
whose transplanted kidney was also cytomegalovirus
negative, 21 had at least one elevated tumour marker.
The difference between the groups was not statistically
significant.
Discussion
From this study it cannot be claimed that elevated
tumour markers in renal transplant patients is indic-
ative of malignant disease. Only one out of seventy
patients had a transient malignancy in the form of a
non-secreting B-cell lymphoma, which was no longer
evident after treatment.
There was no "wash-out" of tumour associated an-
tigens (CA) at the onset of diuresis. As expected, tissue
polypeptide antigen concentrations sank after onset
of diuresis. The same was evident for carcinoem-
bryonic antigen, where pre-operatively elevated values
(17/70 patients) fell to within the reference range for
healthy individuals during 9 —14 days after onset of
diuresis in 12/17 cases. Of the remaining 5 cases, 3
were concomitant with elevated CA 19-9 concentra-
tions. Carcinoembryonic antigen concentrations
above 12 μg/l were not seen pre-operatively.
Although it is known that almost all "tumour mark-
ers" can be elevated in non-malignant disease (1—4,
13-15), it remains unclear from the literature as to
the role of renal insufficiency and the post renal-
transplant period in the elevation of tumour markers,
which are not purely renally excreted.
Cases et al. (3) describe elevated tumour marker con-
centrations in 30 patients with chronic renal failure
and 36 patients on haemodialysis. They found ele-
vated carcinoembryonic antigen in one third of the
chronic renal failure group and in 47% of the patients
undergoing haemodialysis. These figures are consid-
erably higher than those found in the present study,
even when considering the pre-transplant values. The
same authors found elevated CA 125 concentrations
in 18% of the chronic renal failure and 36% of the
haemodialysis patients, which compare well with the
figures in this study (41%). Cases and coworkers (3)
also found elevated concentrations of carcinoem-
Eur. J. Clm. Chem. Clin. Biochem. / Vol. 31,1993 / No. 2
Wood et al.: Tumour markers in renal transplant patients 81
bryonic antigen, CA 50 (similar in structure to CA
19-9) and neuron-specific enolase and squamous cell
carcinoma-antigen in chronic renal failure, which led
the authors to postulate these markers as being un-
reliable in such patients. CA 15-3 and CA 19-9 ele-
vations were much rarer, which coincides with the
findings of the present study.
Zeferos et al. (7) have studied tumour markers in
renal transplant patients and compared the results
with those from healthy controls and patients on
chronic haemodialysis. They found that concentra-
tions of otj-foetoprotein, CA 15-3 and carcinoem-
bryonic antigen were significantly higher in haemo-
dialysis patients than in controls or renal transplant
patients. In contrast, CA 125 and CA 19-9 concen-
trations were not different in all three groups. Al-
though the findings of the present study are in agree-
ment, as far as carcinoembryonic antigen is con-
cerned, they differ with respect to CA 19-9 and CA
125. Zeferos and coworkers concluded that the two
latter markers "can be considered as reliable tumour
markers in patients undergoing haemodialysis or kid-
ney transplantation". The same authors query the
significance of elevated CA 15-3 concentrations after
renal transplantation.
Filella et al. (8) suggest a renal metabolism for car-
cinoembryonic antigen because of elevated concentra-
tions found in renal insufficiency, although renal elim-
ination could equally well be postulated to explain
elevated carcinoembryonic antigen in such patients.
The "wash-out" of carcinoembryonic antigen after
onset of diuresis, as seen in this study, would tend to
support the elimination theory.
Ammon and coworkers (9) found no difference in CA
125 concentrations in healthy subjects and patients
with renal insufficiency, although elevated carcinoem-
bryonic antigen (24% > 5 ^), CA 15-3 (20% > 30
kU/1) and CA 19-9 (14% > 40 kU/1) concentrations
were seen in the same group of patients. As malignant
disease had been excluded, Ammon and coworkers
concluded that "it seemed likely that the terminal
renal insufficiency plays a causal role" in the elevation
of tumour markers seen in this group.
In the present study, which comprised over 8500 single
measurements of the 5 tumour markers investigated
during a long-term study encompassing two years,
the results shed some light on the pre-, peri- and post-
operative periods in patients subjected to renal trans-
plantation. There are, however many questions still
to be answered as to why certain patients have ele-
vated concentrations of certain tumour markers with
no evidence of malignant disease.
In addition, it must be stated although the antibodies
for the different commercial kits for the tumour as-
sociated antigen (CA) tumour markers studied here
are supplied by the same firm, this does not guarantee
the same results for the same analyte, if different kits
are used. This is especially true for CA 19-9 and CA
72-4 (Wood, unpublished observations).
The use of different reference points for defining
"normal" and "elevated" values further complicates
comparison of results. There are considerable differ-
ences between the reference range found for a defined
population, the "normal ranges" given by the kit
producer, and the "cut-off values for defined diag-
nostic specificity and sensitivity.
The conclusions which can be made from this study
are that single isolated determinations of CA 125 and
CA 19-9 are not reliable indicators of malignancy in
renal transplant patients. Because isolated CA 15-3
concentrations are also found in these patients, care
must be taken in interpreting elevated concentrations.
Tissue polypeptide antigen concentrations fluctuate
with diuresis, a point known for several years (1, 2)
but still not mentioned in the kit instructions.
Carcinoembryonic antigen concentrations may be
slightly elevated before transplantation, but usually
return within the reference range for healthy individ-
uals shortly after onset of diuresis, although concom-
itantly elevated concentrations of carcinoembryonic
antigen and CA 19-9 pre-operatively do not always
fall after transplantation and onset of diuresis.
Although some categorisation and grouping of results
was possible, the study emphasised the individuality
of the results from each patient, a point which must
be borne in mind when interpreting tumour marker
results from such patients.
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